 |
|
|
|||||
Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at ASCO 2025. The stock rose 2.2% on Monday, with analysts maintaining a 'Buy' rating.
Category:
News and Media
DCM Shriram's shares surged by 10.5% following a robust Q4 FY25 performance, with net profit soaring 51.9% to Rs 178.9 crore. Revenue climbed 19.9% to Rs 2,876.7 crore, driven by strong segment results and improved EBITDA margins of 14.1%. The board has proposed a final dividend of Rs 3.40 per share.
Category:
News and Media
In an exclusive interview with ETMarkets, Lakhotia shares his ideal portfolio mix for this age group, highlighting a 50% allocation to equities, 20% to gold, 10% to REITs or international funds, and 20% to debt instruments.
Category:
News and Media
From the tactical success of the Elever FactorShields Fund, which delivered 20% returns in FY25, to sharp views on the US-led macro shifts and sector rotation strategies, Aggarwal outlines how investors can align portfolios for stability and long-term alpha. Edited Excerpts
Category:
News and Media
In the Nifty200 pack, nine stocks' close prices crossed above their 200 DMA (Daily Moving Averages) on May 05, according to stockedge.com's technical scan data. The 200-day DMA is used as a key indicator by traders for determining the overall trend in a particular stock. As long as the stock is priced above the 200-day SMA on the daily time frame, it is generally considered to be an overall uptrend. Take a look:
Category:
News and Media
Sites : [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] next »